Allium's bulbar stent provides option to treat patients with
strictures
25 March 2009
Allium Group has announced that its CE certified Urethral Bulbar
stent will now be accessible to patients in Europe. Offering a viable
solution, urologists who are not experts in urethral reconstructive
surgery can now treat patients with recurrent strictures by inserting
the urethral bulbar stent as an office outpatient procedure.
European distribution of the stent will enable patients to select a
minimally invasive procedure to manage their recurring stricture.
The Bulbar Urethral Stent is Allium's latest in a line of stent
products to launch in Europe. Commenting on Allium's leading role in
filling the market gap, Limor Domnitz Gishri, CEO of Allium Medical
said, "Medical stents have emerged as a therapeutic tool to treat
patients with obstructions and strictures given its minimally invasive
characteristics. With Allium's Bulbar Urethral Stent now available to
the wider European medical community, more patients will have the option
to forego repeated dilating procedures or surgery for a simple procedure
which will enable the attainment of a greater quality of life."
The Bulbar Urethral Stent (BUS) is a large caliber, removable stent
designed to fit the dimensions of the normal anatomy and function of the
male bulbar urethra. Developed to treat recurrent bulbar urethral
strictures, the stent's super elastic skeleton allows comfort to the
patient, specifically when sitting on hard surfaces, without
compromising its shape to keep the stented urethra open.
Other than palliative measures such as repeated dilations or optical
urethrotomy, or specialized reconstructive surgery there is no other
treatment for this condition. Allium Medical's one-year stents,
specifically designed to fit the contours of the bulbar urethral lumen,
prevents sphincteric dysfunction that may cause incontinence while
offering a removable and safe method of alleviating stricture
recurrence. Studies have shown that temporary stents left indwelling for
a period of 12-14 months can prevent recurrent stenosis in up to 70% of
patients.
"Until recently, the limited use of temporary stents in Europe has
been an under explored option to treat recurrent urethral strictures due
to a lack of an anatomically and functionally compatible stent. Allium's
next-generation urethral bulbar stent, used as a therapeutic tool,
creates newfound opportunities to treat stenoses and enables non
specialized urologists to effectively perform the simple procedure,"
commented Professor Daniel Yachia, a world-wide known expert on
urological stents and CSO of Allium Medical.
Allium's stents are currently being distributed through numerous
partners in various European markets including Italy, United Kingdom,
Germany and Austria, Benelux, Spain, Greece, Scandinavia and South
Africa.
Bookmark this page